Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-12-06

FDA Approved: TYKERB — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for Tykerb (lapatinib) from Novartis Pharmaceuticals Corporation, approving an additional indication or labeling update …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tykerb (lapatinib)

Snippet

SUPPL AP for TYKERB (LAPATINIB)